[April 29, 2016]

Alpha- Antitrypsin Deficiency Pipeline Report H1 2016 - Review of 19 Companies & Drug Profiles - Research and Markets

Research and Markets has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Apha- Antitrypsin Deficiency Overview
3. Therapeutics Development
4. Pipeline Products for Alpha- Antitrypsin Deficiency - Overview
5. Pipeline Products for Alpha- Antitrypsin Deficiency - Comparative Analysis
6. Alpha- Antitrypsin Deficiency - Therapeutics under Development by Companies
7. Alpha- Antitrypsin Deficiency - Therapeutics under Investigation by Universities/Institutes
8. Alpha- Antitrypsin Deficiency Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Alpha- Antitrypsin Deficiency - Products under Development by Companies
13. Alpha- Antitrypsin Deficiency - Products under Investigation by Universities/Institutes
14. Alpha- Antitrypsin Deficiency - Companies Involved in Therapeutics Development

• Alnylam Pharmaceuticals, Inc.
• Annapurna Therapeutics
• Applied Genetic Technologies Corporation
• Arrowhead Research Corporation
• Carolus Therapeutics, Inc.
• Cevec Pharmaceuticals GmbH
• Dicerna Pharmaceuticals, Inc.
• Digna Biotech, S.L.
• Editas Medicine, Inc.
• Grifols, S.A.
• iBio, Inc.
• Inhibrx
• International Stem Cell Corporation
• Ionis Pharmaceuticals, Inc.
• Kamada Ltd.
• Polyphor Ltd.
• ProMetic Life Sciences Inc.
• rEVO Biologics, Inc.
• Sangamo BioSciences, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005579/en/

[ Back To TMCnet.com's Homepage ]